Bronchogen

Ion Peptide

$79.00

1 vial · vial

Mechanism of Action

Bronchogen's proposed mechanism is the standard Khavinson short-peptide bioregulator model applied to bronchial and respiratory epithelium. The framework, developed at the St. Petersburg Institute of Bioregulation and Gerontology across roughly three decades, proposes a three-stage mechanism: passive membrane permeation, nuclear import by diffusion, and sequence-selective chromatin interaction producing tissue-appropriate gene expression changes.

Step 1 — Absorption and distribution. At approximately 430 daltons (H-Ala-Glu-Asp-Pro-OH), Bronchogen is small and sufficiently polar to cross phospholipid bilayers passively. Khavinson's tritiated peptide biodistribution studies — conducted across multiple tetrapeptides with shared methodology — reported rapid tissue uptake after intraperitoneal or oral dosing, with radioactive label recovered from lung, liver, brain, and thymus within minutes (Khavinson et al., 2014). Those experiments did not separate intact peptide from catabolite pools, so the claim that Bronchogen delivers intact AEDP to bronchial epithelial nuclei rests on inference rather than direct structural confirmation.

Step 2 — Bronchial targeting. The Khavinson-framework claim is that AEDP shows tissue-preferential uptake in bronchial tissue, explaining the respiratory-selective pharmacological effect. The supporting data are radiolabel-uptake measurements in bulk tissue homogenates. Modern biodistribution methods — LC-MS/MS intact-peptide quantification, immuno-histochemistry on a dose-matched vehicle control, single-cell transcriptomics on airway epithelium after dosing — have not been applied to Bronchogen in English-indexed literature. Whether the bronchial selectivity is real, artefactual, or simply a product of the Khavinson-framework narrative is open.

Step 3 — Chromatin modulation. Once inside the bronchial epithelial cell, the Khavinson framework proposes that AEDP diffuses through nuclear pores and makes sequence-selective contacts with exposed DNA regions and histone tails. The proposed consequence is preferential decondensation of silenced chromatin regions carrying genes associated with epithelial regeneration — ciliogenesis, surfactant production, tight-junction proteins, mucin transcription programmes. Russian in vitro work on ciliated epithelium cultures describes morphological improvements in cilia structure and mucociliary index after Bronchogen exposure (Chalisova et al., 2015). The data do not rise to the level of genome-wide ChIP-seq, ATAC-seq, or CUT&RUN — methods that have not been applied to short Khavinson peptides in any published work.

Alternative conservative framing. A more conservative mechanistic interpretation treats Bronchogen as a mixture of four amino acids (alanine, glutamate, aspartate, proline) delivered in a rapidly absorbed short-peptide form. In that framing, biological effects observed in Russian studies could reflect substrate delivery for protein synthesis in rapidly turning-over epithelium, non-specific signalling effects of individual amino acids (proline as a collagen-precursor and HIF-α modulator, glutamate as an excitatory signal in chemosensory systems), or simple supportive nutrition to tissue under stress. Under this framing, any amino-acid mixture delivered via comparable route would be mechanistically equivalent — which makes the specificity claim for AEDP unlikely to survive rigorous pharmacological testing.

Receptor pharmacology. No G-protein-coupled receptor, nuclear receptor, or defined enzyme target has been identified for Bronchogen. It does not bind β2-adrenoceptors (the molecular target of salbutamol and formoterol), muscarinic receptors (the target of tiotropium), leukotriene receptors, or any of the well-characterised signalling pathways in airway smooth muscle and epithelium. The absence of a defined target is the hallmark of the Khavinson framework — bioregulators are claimed to act through chromatin — but it also explains why Western respiratory pharmacology has not adopted the compound.

Relation to other Khavinson peptides. Bronchogen is the defined-sequence analogue of Chonluten, a bovine-bronchial polypeptide extract sold as a parallel bioregulator product. Both are positioned as respiratory bioregulators; Bronchogen is the synthetic, chemically-characterised short peptide while Chonluten is the undefined natural extract. This dual positioning — a polypeptide "parent" and a short-peptide "sibling" — repeats throughout the Khavinson programme and reflects a conscious strategy to produce pure, defined-composition alternatives to the original extract-based bioregulators. Whether the strategy succeeds in reproducing biological effects is the open question.

Comparison to evidence-graded respiratory mechanisms. Inhaled β2-agonists cause bronchodilation through smooth-muscle relaxation via G-protein signalling (measured, quantified, structurally mapped). Inhaled corticosteroids suppress eosinophilic airway inflammation through glucocorticoid receptor activation (RCT-validated, mechanism understood to molecular detail). Muscarinic antagonists block parasympathetic bronchoconstriction (mapped to M3 receptor occupancy). Mucolytic agents (NAC, carbocysteine) alter mucin disulphide chemistry directly (chemistry understood). Bronchogen, even if it works as claimed, sits at a completely different level of mechanistic specification — it is a hypothesis about chromatin, not a measured pharmacological tool.

Bronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "bronchial bioregulator" intended to support respiratory epithelium and ciliated-airway function in chronic obstructive pulmonary disease (COPD), chronic bronchitis, and age-related decline of mucociliary clearance. It is usually described in Khavinson-family publications as the tetrapeptide Ala-Glu-Asp-Pro (AEDP), sometimes written H-Ala-Glu-Asp-Pro-OH or A-E-D-P. It sits alongside Pinealon, Thymogen, Vilon, Epitalon, and Livagen within the Khavinson short-peptide bioregulator family, and it is the defined-sequence counterpart to a polypeptide preparation called Chonluten that is prepared from bovine bronchial mucosa — a relationship that mirrors the Thymogen/Thymalin and Livagen/Stamakort pattern throughout the bioregulator programme.

Outside Russia and a small handful of former-Soviet pharmacology journals, Bronchogen is not a registered drug, not an FDA- or EMA-reviewed supplement, and not a member of the WADA Prohibited List. There are no phase II or phase III randomised trials indexed in PubMed or ClinicalTrials.gov, and the peptide does not appear in GOLD, ERS, or NICE guidelines for COPD or chronic bronchitis. The published Russian work — most of it authored or co-authored by Khavinson and colleagues, with occasional collaborators in Almaty and Minsk — comprises in vitro cell-culture experiments in bronchial epithelial cells, small rodent studies of induced lung injury, and a handful of uncontrolled observational case series in elderly patients with chronic respiratory disease (Khavinson et al., 2011; Chalisova et al., 2015; Kuznik et al., 2011).

The central claim made for Bronchogen is the standard Khavinson short-peptide model applied to the bronchial epithelium: passive membrane permeation, nuclear import, and sequence-selective chromatin modulation that preferentially up-regulates genes associated with epithelial regeneration, mucociliary function, and surfactant production. The specific-tissue selectivity claim — that AEDP targets bronchial rather than hepatic or pineal tissue — is not supported by structural biology or by modern biodistribution studies, and rests on extrapolation from the aggregate Khavinson framework. The hypothesis is internally consistent within the Khavinson programme; it is also substantially less validated than the pharmacology of even moderately well-studied respiratory drugs.

BodyHackGuide covers Bronchogen because it is sold online in post-Soviet supplement channels (typically as 20 mg oral capsules containing an undisclosed quantity of actual peptide) and because it shows up in longevity-stack discussions where the speaker frames it as a respiratory-support bioregulator alongside proven interventions. We describe what is known, what is claimed, and what is missing — and we steer readers who want evidence-graded respiratory support toward interventions with substantial replication: smoking cessation, pulmonary rehabilitation, inhaled bronchodilators and corticosteroids for obstructive disease, GLP-1 agonist-mediated weight loss for obesity-related restrictive disease, and, where specifically indicated, biologics such as benralizumab, mepolizumab, or dupilumab. Bronchogen is a plausible hypothesis. It is not, in 2026, an evidence-graded respiratory therapy.

IUPAC Name

L-Alanyl-L-glutamyl-L-aspartyl-L-leucine

CAS Number

90203-90-0

Molecular Formula

Ala-Glu-Asp-Leu

Molecular Mass

459.45 g/mol

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Interaction Matrix

Get Bronchogen Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it. Current lowest: $79.00

Related Compounds

Related Articles

Ion Peptide

$79.00

Data Completeness

Research Credibility